The impact of health technology assessments: an international comparison
暂无分享,去创建一个
Panos Kanavos | E. Nicod | P. Kanavos | Elena Nicod | Stacey van den Aardweg | Stephen Pomedli | Steve Pomedli
[1] J. Cairns. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. , 2006, Health policy.
[2] C. Mitton,et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. , 2006, Health affairs.
[3] C. McCabe,et al. Orphan drugs and the NHS: should we value rarity? , 2005, BMJ : British Medical Journal.
[4] Panos Kanavos,et al. Assessing the economic challenges posed by orphan drugs , 2007, International Journal of Technology Assessment in Health Care.
[5] Martin McKee,et al. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union , 2008 .
[6] D. Menon,et al. Health technology assessment in Canada: 20 years strong? , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.